Evidence map›Paper›PMID 41257133›Full record

ArticleCureus2025

Pituitary Gland Metastases As the Initial Presentation of Lung Adenocarcinoma: A Case Report.

Angela E Russo, Hannah Johnson, Ximena Jordan Bruno, Christopher J Anker, Hibba Rehman

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Angela E RussoInternal Medicine, University of Vermont Medical Center, Burlington, USA.
Hannah JohnsonPediatrics, University of Vermont, Burlington, USA.
Ximena Jordan BrunoOncology, Perelman Center for Advanced Medicine, Philadelphia, USA.
Christopher J AnkerRadiation Oncology, University of Vermont Medical Center, Burlington, USA.
Hibba RehmanOncology, University of Vermont Medical Center, Burlington, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pituitary gland metastases (PMs) are rare and typically asymptomatic, often discovered incidentally in patients with known malignancies. Symptomatic PMs as the initial presentation of cancer are uncommon. We report a case of a 52-year-old woman with no prior oncologic history who presented with progressive unilateral vision loss, headaches, and systemic symptoms. Imaging revealed a sellar and suprasellar mass, and endocrine evaluation indicated both anterior and posterior pituitary dysfunction. Surgical resection and histopathological analysis confirmed metastatic adenocarcinoma of the lung. The patient was treated with radiation to the sellar region and systemic chemoimmunotherapy, resulting in radiologic improvement and partial improvement in vision four months after the initiation of treatment. This case underscores the importance of considering metastatic disease in the differential diagnosis of pituitary masses, particularly in patients with acute neuro-ophthalmologic and endocrine abnormalities. Though difficult to distinguish clinically and radiologically from primary sellar tumors, the presence of diabetes insipidus may indicate a PM diagnosis given its rarity in pituitary adenoma cases. Early recognition and multidisciplinary intervention are critical to improving outcomes and preserving function in such rare and complex presentations.

Indexed as

chemoradiation therapymetastatic non-small cell lung cancerneuroimaging studiespituitary metastasisvisual field defect

Identifiers

PMID41257133
PMCPMC12620922

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.